Media Resources

Living Cell Technologies Receives Health Minister's Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics

21 October, 2008 - Living Cell Technologies today announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell®, LCT's lead product candidate for the treatment of insulin dependent (Type 1) diabetes.

Click here to download this release in PDF format.

NOTICE OF ANNUAL GENERAL MEETING

07 October, 2008 - Living Cell Technology gives notice of their Annual General Meeting

 to be held at to be held at 1.00 pm on Thursday 6 November 2008 at Stamford Plaza Hotel, Clare Room, 150 North Terrace, Adelaide SA

Click here to download this release in PDF format.

Living Cell Technologies Announces Appendix 4C Quarterly Report

31 July, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY)

today announced that the cash balance at the end of the quarter was $10,767,335 compared to $12,689,973 at the end of the quarter to March 31st 2008.

Click here to download this release in PDF format.

Living Cell Technologies Reports Clinical Benefit for All Patients in Diabetes Trial

22 July, 2008 - Melbourne, Australia and Auckland, New Zealand. Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY)

today released further interim results describing clinical benefit in all patients who have received implants of DiabeCell®, the Company’s encapsulated porcine islet cells for the treatment of type 1 diabetes.

Click here to download this release in PDF format.

LCT Quarterly Newsletter

01 July, 2008 -

Living Cell Technologies present the July issue of the quarterly investor newsletter.

Click here to download this release in PDF format.

LCT lists on the International OTCQX

03 June, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY)

today announced that it has listed its American Depositary Receipts (“ADRs”) on the International OTCQX and began trading Monday, June 2nd in the United States.

Click here to download this release in PDF format.

OTCQX listing planned to further open exposure to US investors

08 May, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY)

today announced it has applied to list its American Depository Receipt (ADR) program on the International OTCQX to increase the Company’s exposure to U.S. investors.

Click here to download this release in PDF format.

LCT showcases proprietary nanotech

02 April, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTCQX:LVCLY)

today announced that Dr. Paul Tan, LCT CEO and Dr. Anil K Anal, LCT Material Scientist, presented data at a session on nanotechnology at the NZBio 2008 Conference in Auckland, New Zealand.

Click here to download this release in PDF format.

Living Cell Technologies and US- Based Barbara Davis Center to collaborate on Diabetes Clinical Trial Program

27 February, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK)

today announced that the Company has signed a term sheet with the Barbara Davis Center for Childhood Diabetes (BDC) to establish a diabetes clinical trial program in Denver, Colorado.

Click here to download this release in PDF format.

Diabetes Trial Supported By US-Based Diabetes Foundation

12 February, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK)

today announced that the US based Children with Diabetes Foundation (CWDF), has offered its support in raising funds for LCT’s DiabeCell® clinical trials for people with type 1 diabetes. The foundation has established a fund which allows supporters of diabetes research to contribute tax deductible donations towards the trials.

Click here to download this release in PDF format.

Living Cell Technologies to Receive US$6.0M through Exercise of Option

09 January, 2008 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK)

today announced that Palmert Members Limited (a British Virgin Island company) will purchase 24,150,408 ordinary shares of LCT at A$0.29 per share for an aggregate purchase price of US$6.0 million. Palmert will make this investment through exercising an option that was granted to NaviGroup Management Limited and assigned to Palmert by NaviGroup. The option, which expires on January 24, 2008 was exercised on December 20, 2007 and allows the holder to purchase up to US$6.0 million of LCT’s ordinary shares at 80% of the 30-day average closing bid price per ordinary share of the Company. The issue of these shares will occur at an exchange rate of US$0.8567 per AU$1.00 and is subject to certain shareholder approvals.

Click here to download this release in PDF format.

Living Cell Technologies Has the Funds to Capatilise on the Opportunities of 2008 - Australian Investor Article

01 January, 2008 - The Australian Investor

2007 was an exciting year for Living Cell Technologies, with the commencement of its clinical trials for its diabetes product in Russia. The preliminary results of this trial have been very encouraging and should provide a solid foundation for the Company moving forward in 2008.

Click here to download this release in PDF format.